


Geistlich TauroSept®

What your catheter needs.


Original
Taurolidine

2% strength




Strong protection.
Thorough treatment.

Characteristics



Prevention of catheter occlusion

- › Inhibition of staphylocoagulase activity⁷
- › Evidence for inhibition of blood coagulation factors and prevention of surface activation of platelets^{8,9}



Prevention of catheter-related blood stream infections (CRBSI)


- › Broad bactericidal and fungicidal spectrum¹
- › Effective against antibiotic-resistant bacteria²
- › No development of bacterial resistance known³

Geistlich TauroSept® Catheter lock solution



Treatment of colonized catheters

- › Resolves the catheter biofilm^{4,5}
- › Detoxifies endo- and exotoxins⁶



TauroSept® can be used with any vascular access device

Follow the manufacturer's instructions for the particular catheter utilized.¹²



Very good tolerance

- › No heparin, no citrate¹²
- › Can be flushed in adults¹⁰
- › Rapidly metabolized to Taurine, H₂O and CO₂¹¹

1 Torres-Viera C et al. Antimicrob. Agents Chemoth. 2000. 44 (6):1720-1724.
2 Traub WH et al. Chemotherapy. 1993. 39 (5):322-30.
3 Olthof ED et al. Clin Nutr. 2013. 32 (4):538-42.
4 Koldehoff M and Zakrzewski JL. Int J Antimicrob Agents. 2004. 24 (5):491-5.
5 Weber M et al. Zentralbl Chir. 2009. 134 (4):350-6.

6 Blenkarn JI. Surg. Res. Comm. 1987. 2:149-155.
7 Reinmüller J et al. Hämostaseologie 1999. 19:94-7.
8 Kaptanoglu L et al. Eur J of Physiol 2008. 578:238-41.
9 Reinmüller J. Zentralbl Chir. 1999. 124 (Suppl 4):13-8.
10 Gong L et al. J Clin Pharmacol 2007. 47(6): 697-703.

Benefits

-84%

Catheter-related blood stream infections (CRBSI)^{13-16*}

+80%

Successful treatment of catheter infections^{4,5}

-71%

Catheter occlusions^{13**}

-51%

Overall treatment costs^{16,17***}

11 Steinbach-Lebbin C et al. Drug. Res. 1982. 32(12):1542-1546.

12 TauroSept®-Instructions for Use. 06/2015.

13 Olthof ED et al. PLoS One. 2014. 9 (11):e111216.

14 Bisseling TM et al. Clin Nutr. 2010. 29 (4):464-8.

15 Jurewitsch B and Jeejeebhoy KN. Clin Nutr. 2005. 24 (3):462-5

16 Wouters Y et al. AP & T. 2018. 48 (4):410-422.

17 Arnoriaga Rodriguez M et al. 2018. Nutr Hosp. 35(4):761-766.

* Compared to 100/150 U/ml Heparin and Saline

** Compared to 150 U/ml Heparin

*** Compared to 0.9 % Saline



More details about TauroSept®:
www.geistlich-medical.com

Manufacturer

Geistlich Pharma AG
Bahnhofstrasse 40
6110 Wolhusen, Switzerland
Phone +41 41 492 55 55
Fax +41 41 492 56 39
www.geistlich-medical.com

Guidelines

European Renal Best Practice (ERBP)¹⁸

ESPEN guideline on home parenteral nutrition¹⁹

GAVeCeLT consensus²⁰

Commission for hospital hygiene and infection prevention (KRINKO)²¹


S3-Guideline of the German Society for Nutrition Medicine (DGEM)²²

Geistlich TauroSept® – putting our tradition into practice

- › Long lasting experience including clinical studies
- › Taurolidine produced by Geistlich Pharma in Switzerland
- › Geistlich Pharma AG is a Swiss family company founded in 1851

“The fingerprint represents the uniqueness of Geistlich Pharma and the Geistlich family. We constantly strive to support our customers and patients and our relentless pursuit of being: **EXACTLY** like no other.”

Dr. Andreas Geistlich
President of the Board of Directors 5th Generation
Family Member since the Company was founded.



18 Vanholder R et al. NDT Plus. 2010. 3:234–246.
19 Pironi L et al. Clin Nutr. 2020. 39(6):1645–1666.
20 Pittiruti M et al. J Vasc Access. 2016. 17(6):453–464.
21 Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut, Bundesgesundheitsbl 2017;60:171–206.
22 Lamprecht G et al. S3-Leitlinie der Deutschen...
Aktuel Ernährungsmed 2014; 39: e57–e71